Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

By Pfeiffer Per   Nielsen Dorte   Yilmaz Mette   Iversen Anja   Vejlø Christian   Jensen Benny Vittrup  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 697-701

Informa Healthcare

Access to resources Recommend Favorite

Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study

By Santini Daniele   Vincenzi Bruno   Schiavon Gaia   Di Seri Marisa   Virzí Vladimir   Spalletta Bruno   Caricato Marco   Coppola Roberto   Tonini Giuseppe  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 613-620

Springer Publishing Company

Access to resources Recommend Favorite

Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences

By Astrup Jensen Søren   Thomsen Lønborg Jacob   Benn Sørensen Jens  

Acta Oncologica, Vol. 45, Iss. 1, 2006-02 ,pp. : 67-76

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer

By Andersen Maria   Schønnemann Katrine R.   Yilmaz Mette   Jensen Helle A.   Vestermark Lene W.   Pfeiffer Per  

Acta Oncologica, Vol. 49, Iss. 8, 2010-11 ,pp. : 1246-1252

Informa Healthcare

Access to resources Recommend Favorite

Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer

By Larsen Finn Ole   Boisen Mogens Karsbøl   Fromm Annelene L.   Jensen Benny Vittrup  

Acta Oncologica, Vol. 51, Iss. 2, 2012-02 ,pp. : 231-233

Informa Healthcare

Access to resources Recommend Favorite